GW Pharmaceuticals Plc (GWPH):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:GW Pharmaceuticals Plc (GWPH) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7339
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the treatment of spasticity due to multiple sclerosis. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. GW Pharmaceuticals is also developing products for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis, infantile spasms, epilepsy syndrome, glioma, schizophrenia, autism among others. The company has subsidiaries in Australia, the US, England and Wales, and Guernsey. GW Pharmaceuticals is headquartered in Cambridgeshire, the UK.

GW Pharmaceuticals Plc (GWPH) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
GW Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
GW Pharmaceuticals Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
GW Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
GW Pharmaceuticals Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
GW Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
GW Pharmaceuticals Plc, Medical Equipment, Deal Details 10
Private Equity 10
Mentor Capital Invests USD1 Million in GW Pharma 10
Equity Offering 11
GW Pharma Raises USD345.2 Million in Public Offering of American Depositary Shares 11
GW Pharma Raises USD317.4 Million in Public Offering of Shares 13
GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 15
GW Pharma Completes Public Offering Of American Depositary Shares For US$101 Million 17
Acquisition 19
GW Pharma May Sell Itself 19
GW Pharmaceuticals Plc – Key Competitors 20
GW Pharmaceuticals Plc – Key Employees 21
GW Pharmaceuticals Plc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Aug 07, 2018: GW Pharmaceuticals reports fiscal third quarter 2018 financial results and operational progress 23
May 08, 2018: GW Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results 25
Aug 07, 2017: GW Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results 26
May 09, 2017: GW Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress 28
Feb 07, 2017: GW Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Progress 30
Corporate Communications 31
Dec 21, 2017: GW Pharmaceuticals Announces the Appointment of Three New Independent Members to its Board of Directors 31
May 15, 2017: GW Pharmaceuticals Announces Research & Development Management Appointments 32
Mar 07, 2017: GW Pharmaceuticals Announces the Appointment of Scott Giacobello as Chief Financial Officer and Adam George as Managing Director – UK 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
GW Pharmaceuticals Plc, Medical Equipment, Key Facts, 2017 2
GW Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
GW Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
GW Pharmaceuticals Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
GW Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
GW Pharmaceuticals Plc, Deals By Market, 2012 to YTD 2018 8
GW Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Mentor Capital Invests USD1 Million in GW Pharma 10
GW Pharma Raises USD345.2 Million in Public Offering of American Depositary Shares 11
GW Pharma Raises USD317.4 Million in Public Offering of Shares 13
GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 15
GW Pharma Completes Public Offering Of American Depositary Shares For US$101 Million 17
GW Pharma May Sell Itself 19
GW Pharmaceuticals Plc, Key Competitors 20
GW Pharmaceuticals Plc, Key Employees 21
GW Pharmaceuticals Plc, Other Locations 22
GW Pharmaceuticals Plc, Subsidiaries 22

List of Figures
GW Pharmaceuticals Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
GW Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
GW Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
GW Pharmaceuticals Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
GW Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
GW Pharmaceuticals Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
GW Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
GW Pharmaceuticals Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[GW Pharmaceuticals Plc (GWPH):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Endesa SA (ELE):電力:M&Aディール及び事業提携情報
    Summary Endesa SA (Endesa), a subsidiary of Enel SpA, is an electric utility. It generates, distributes, and sells electricity. The company produces electricity in hydro, thermal, nuclear, combined cycle, and renewable and cogeneration plants. Endesa also supplies electricity and gas, and provides o …
  • American Bio Medica Corp (ABMC):企業の財務・戦略的SWOT分析
    Summary American Bio Medica Corp (ABMC) is a biotechnology company that develops, manufactures and markets immunoassay test kits. The company’s products include Rapid TOX, a point of collection testing product that detects 1-10 drugs of abuse in a urine specimen; Rapid One, a test cassette which is …
  • Asian Infrastructure Investment Bank-エネルギー分野:企業M&A・提携分析
    Summary Asian Infrastructure Investment Bank (AIIB) is a multilateral financial institution. It focuses on the development of infrastructure and other productive sectors in Asia. The company offers sovereign and non-sovereign finance for sustainable projects in energy and power, transportation and t …
  • Hanmi Pharmaceuticals Co Ltd (128940)-製薬・医療分野:企業M&A・提携分析
    Summary Hanmi Pharmaceuticals Co Ltd (Hanmi Pharma), a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The company’s prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counte …
  • Theranostics Health Inc:医療機器:M&Aディール及び事業提携情報
    Summary Theranostics Health Inc (Theranostics), a subsidiary of Avant Diagnostics Inc is a healthcare service provider that offers protein based solutions. The company provides protein based discovery and translational research services. Its products include molecular navigation of targeted therapie …
  • NanoCarrier Co Ltd (4571):企業の財務・戦略的SWOT分析
    Summary NanoCarrier Co Ltd (NanoCarrier) is a drug development company that develops and produces pharmaceuticals using micellar nanoparticles technology. The company’s pipeline products include NC-6004, NC-4016, NC-6300, VB-111, NC-6201 and NK105. It offers siRNA micelle, protein micelle, DACH-plat …
  • HiberGene Diagnostics Ltd:医療機器:M&Aディール及び事業提携情報
    Summary HiberGene Diagnostics Ltd (HiberGene Diagnostics) is a medical equipment company that manufactures, develops and markets molecular diagnostic tests for human infectious diseases using the LAMP technology. The company’s products include HG C. Difficile, HG Meningococcus, HG Group B Streptococ …
  • aap Implantate AG (AAQ):企業の製品パイプライン分析2018
    Summary aap Implantate AG (aap Implantate) is a medical device company, which develops, manufactures and markets trauma products and biomaterials for orthopedic treatment. Its products include locked plating systems for anatomical reduction, cannulated screws, standard plates and screws for osteosyn …
  • SCB Life Assurance Public Company Limited:戦略・SWOT・企業財務分析
    SCB Life Assurance Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary SCB Life Assurance Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • ProMIS Neurosciences Inc (PMN):企業の製品パイプライン分析
    Summary ProMIS Neurosciences Inc (ProMIS), formerly Amorfix Life Sciences Ltd is a development stage biopharmaceutical company which focuses on the development of therapeutic antibodies and diagnostics for the treatment of neurodegenerative disorders. Its major products include tests functional assa …
  • South Jersey Industries, Inc. (SJI):石油・ガス:M&Aディール及び事業提携情報
    Summary South Jersey Industries Inc (SJI) is an energy services holding company that sources and supplies natural gas and electricity. It develops, owns, and operates on-site energy production facilities. The company provides wholesale commodity marketing and fuel management services; and also offer …
  • Oracle Corporation (ORCL):企業の財務・戦略的SWOT分析
    Oracle Corporation (ORCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Open Text Corporation:企業のM&A・事業提携・投資動向
    Open Text Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Open Text Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Pt Bumi Resources Tbk
    Pt Bumi Resources Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Bumi Resources Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Oxford Nanopore Technologies Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Oxford Nanopore Technologies Ltd (Oxford Nanopore), formerly Oxford NanoLabs Ltd., develops disruptive, electronic, and single-molecule sensing system. The company’s products include SmidgION, Flongle, MinION, PromethION and GridION used for the analysis of DNA, RNA, proteins, small molecule …
  • Machavert Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Machavert Pharmaceuticals LLC (Machavert Pharmaceuticals) is a bio-pharmaceutical company which develops novel non-toxic medicines for the treatment of cancer and autoimmune diseases. Its lead drug candidate MP1000, a nanoparticulate liposomal phospholipid immune-modulating agent exhibits an …
  • Doosan Infracore Co Ltd (042670):企業の財務・戦略的SWOT分析
    Doosan Infracore Co Ltd (042670) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Exandal Corp:企業の戦略・SWOT・財務分析
    Exandal Corp - Strategy, SWOT and Corporate Finance Report Summary Exandal Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • WPX Energy, Inc.:企業の戦略・SWOT・財務情報
    WPX Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary WPX Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Catasys Inc (CATS):企業の財務・戦略的SWOT分析
    Summary Catasys Inc (Catasys) is a healthcare service provider that offers health and reducing claims costs for health plan members with behavioral health (BH) disorders. The company offers OnTrak, a fifty two week intensive outpatient program, treats an overlooked population and members suffering f …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆